augusti 18, 2021

Ectin Research in first day of trading on Spotlight Stock Market

On August 18, 2021, trading in Ectin Research AB’s shares and warrants of series TO 1B on the Spotlight Stock Market began. For details on the share, CEO statement and photos from the launch event – read more here.

Shares are traded under the short name “ECTIN” and ISIN code SE0015987714, warrants of series TO 1B are traded under the short name “ECTIN TO 1B” and ISIN code SE0015988357.

Issue of units prior to listing

The listing on Spotlight was preceded by an issue of units that initially provided the Company with approximately SEK 45 million before issue costs. Through the issue, Ectin has also added approximately 480 new shareholders.

Financial advisor, legal advisor and issuer

Sedermera Fondkommission has acted as financial advisor and Market & Corporate Law Nordic AB legal advisor to Ectin in connection with the issue and listing. Nordic Issuing has acted as an issuing institution.

CEO Anna Sjöblom-Hallén: “This was a milestone for all of us and we’re delighted to begin trading and gathering more support for the continued development of MFA-370. The new listing makes Ectin more visible, and gives new shareholders the opportunity to support and share our goal of establishing MFA-370 as the first oral treatment for metastatic urothelial bladder cancer with few and tolerable potential side effects. Thanks to the capital we receive, we now have the financial opportunities to begin the planned phase l / ll study during H2 2021. We look forward to welcoming new shareholders into the fold – and driving this important new treatment forward.”




For further information please contact:

Anna Sjöblom-Hallén, CEO

Mob: +46 734 30 93 30

About Ectin Research AB

Ectin Research AB pharmaceutical company is developing a novel treatment that eliminates cancer tumors. Its drug candidate MFA-370 will first be trialled for the treatment of metastatic bladder cancer. MFA-370 consists of two existing drugs that have already undergone large-scale clinical trials and are currently widely used in other indications. In preclinical studies MFA-370 has achieved successful results for the treatment of metastatic bladder cancer, and has also shown promising potential in other cancers such as breast, colorectal and prostate cancer cells.